FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Wasman Jane
2. Issuer Name and Ticker or Trading Symbol

ACORDA THERAPEUTICS INC [ ACOR ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President, Intl and GC
(Last)          (First)          (Middle)

420 SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

11/7/2019
(Street)

ARDSLEY, NY 10502
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (right to buy) $2.41 11/7/2019  A   80000     (1)11/7/2029 Common Stock 80000 $0.00 80000 D  

Explanation of Responses:
(1) Options issued under the issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to the options vest in equal quarterly installments over two years beginning on November 7, 2019 with the first quarterly installment vesting on February 7, 2020.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Wasman Jane
420 SAW MILL RIVER ROAD
ARDSLEY, NY 10502


President, Intl and GC

Signatures
/s/ Jane Wasman11/12/2019
**Signature of Reporting PersonDate

Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Acorda Therapeutics Charts.
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Acorda Therapeutics Charts.